Will integrate with Cognos Planning to give leading biotech firm a true
Performance Management solution
BURLINGTON, MASS., October 3 /CNW/ - Cognos (NASDAQ: COGN) (TSX: CSN),
the world leader in business intelligence and performance management
solutions, today announced that Acambis, a leading biotechnology company, has
selected Cognos 8 Business Intelligence (BI) to help better measure
performance against targeted spending plans.
Acambis is a leading biotechnology company that develops novel vaccines
which target unmet medical needs or offer improvements over existing products.
To optimize its investment in research and development, Acambis wanted to
ensure it was spending properly across the organization. The firm looked at a
variety of solutions and chose Cognos 8 BI as its corporate solution to
integrate projects and initiatives and more effectively measure performance
against resource allocation plans. Cognos 8 BI will allow for timely access to
accurate data and facilitate better collaboration and control between function
and project leaders. Acambis executives will now receive reports specifically
tailored to their needs and objectives, enabling them to gain an immediate
sense of their performance status and identify trouble areas in advance.
"Historically it took a long time to produce reports and analyze the
information. Data was difficult to extract and was not always accurately
reflected, which meant the credibility of the report was put in question,"
said Mohammad Hammami, Director of Financial Management, Acambis. "With Cognos
8 BI we will have quicker reporting with accurate data, which means management
will have greater confidence in the information and, more importantly, in the
decisions they make around resource allocation in particular."
As a long time Cognos Planning customer, Acambis will integrate its
financial planning process with Cognos 8 BI to deliver a complete performance
management environment. Cognos Planning helps Acambis forecast and manage its
internal resources - including cash, people and revenues. Cognos BI will help
Acambis measure key performance metrics against these targeted plans, identify
trends, and spot anomalies.
Business intelligence and enterprise planning are key capabilities of the
Cognos Performance Management System, which combines technology, best
practices, analytical applications and solutions, and a broad network of
partners into a single performance management solution for customers. Cognos 8
BI is the only BI product that provides the complete range of BI capabilities
- reporting, analysis, scorecarding, dashboards, business event management,
and data integration - on a single, proven architecture. Cognos 8 Planning
leverages Cognos 8 BI to enable reporting and analysis on real-time plans. For
more information on Cognos Performance Management please visit:
"The pharmaceutical industry is seeing rising R&D costs, which means
companies such as Acambis are looking for ways to identify cost savings and
improve business processes," said Bill Stevens, associate vice president of
life sciences marketing, Cognos. "Acambis, with its expertise in vaccine
development, paired with Cognos' leading performance management solutions,
will enable better decision-making to address its specific needs and keep the
competitive edge required to succeed."
Cognos is a recognized leader in delivering performance management
solutions for the pharmaceutical industry. Currently, 25 of the top 30
pharmaceutical firms rely on Cognos performance management software. In
addition to Acambis, other customers include Novartis, Bayer UK, and Quintiles
Transnational. For more information about Cognos solutions for pharmaceuticals
and life sciences, please visit
(Editor's Note: Due to the length of this URL, it may be necessary to
copy and paste it into your Internet browser's URL address field.)
Acambis is a leading vaccine company developing novel vaccines that
address significant unmet medical needs or substantially improve standards of
care. ChimeriVax-JE, Acambis' most advanced product in its non-biodefence
pipeline, has completed pivotal Phase 3 trials and is currently undergoing
paediatric trials in India. It is partnered with sanofi pasteur and Bharat
Biotech. Acambis' proprietary ChimeriVax technology, developed in association
with St Louis University, has also been used to develop ChimeriVax-West Nile,
which is undergoing Phase 2 clinical testing, making it the most advanced
investigational vaccine against the West Nile virus. Acambis also has the only
vaccine in development against Clostridium difficile bacteria, a leading cause
of hospital-acquired infections. Acambis' influenza programe aims to develop a
universal vaccine against influenza, for which a universal 'A' strain vaccine,
ACAM-FLU-A, is currently being tested in a Phase 1 trial, and also includes
various further vaccine candidates in the research and pre-clinical stages.
Recognized internationally as the leading producer of smallpox vaccines,
Acambis has manufactured its investigational smallpox vaccine, ACAM2000, for
emergency-use stockpiles held by the US Government and 14 others governments
around the world.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and
is listed on the London Stock Exchange (ACM). More information is available at
Cognos, the world leader in business intelligence and performance
management solutions, provides world-class enterprise planning and BI software
and services to help companies plan, understand and manage financial and
Cognos brings together technology, analytical applications, best
practices, and a broad network of partners to give customers a complete
performance system. The Cognos performance system is an open and adaptive
solution that leverages an organization's ERP, packaged applications, and
database investments. It gives customers the ability to answer the questions
-- How are we doing? Why are we on or off track? What should we do about it? -
and enables them to understand and monitor current performance while planning
future business strategies.
Cognos serves more than 23,000 customers in more than 135 countries, and
its top 100 enterprise customers consistently outperform market indexes.
Cognos performance management solutions and services are also available from
more than 3,000 worldwide partners and resellers. For more information, visit
the Cognos Web site at http://www.cognos.com.
Cognos and the Cognos logo are trademarks or registered trademarks of
Cognos Incorporated in the United States and/or other countries. All other
names are trademarks or registered trademarks of their respective companies.
Note to Editors: Copies of previous Cognos press releases and Corporate
and product information are available on Cognos' Web site at
For further information:
For further information: Media Contacts: Cognos, Inc. David DeRosa,
613-738-1338 ext. 3317 firstname.lastname@example.org or Lois Paul & Partners, LLC
Melissa Lane, 781-782-5755 email@example.com or Investor Relations: Cognos,
Inc. John Lawlor, 613-738-3503 firstname.lastname@example.org